Your one point of contact for Actelion services and support
Ventavis
PAH Pathways Interactive Resource Locator
PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more ยป
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
For more information on Ventavis, consult the full Prescribing Information or visit the Ventavis Web site.
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
Important safety information about Ventavis:
In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
Please see full Prescribing Information
Tracleer
Please see full Prescribing Information, including BOXED WARNING and Medication Guide for Tracleer.